Monopar director Kim Tsuchimoto sells $455k in common stock

Monopar Therapeutics director Kim R. Tsuchimoto sold a total of $455,566 worth of common stock on August 26, 2026, as reported in a recent SEC Form 4 filing. The director traded 4,090 shares of Monopar Therapeutics (NASDAQ: MNPR), with prices fluctuating between $108.07 and $114.34 per share. The sales came after Monopar's shares experienced a 227% return over the past year and a 108% gain in the last six months.

However, according to InvestingPro analysis, the stock appears overvalued at its current price. The sales were facilitated by a Rule 10b5-1 trading plan adopted by Tsuchimoto on May 27, 2026. After the transactions, Tsuchimoto personally holds 7,396 shares of Monopar Therapeutics common stock. Monopar Therapeutics has recently been involved in several developments, including initiating a rolling New Drug Application (NDA) submission for ALXN1840, which received FDA authorization for partial submissions.

Analysts have reacted to these developments, with several price target updates and rating adjustments. Monopar Therapeutics has also strengthened its leadership by appointing several commercial executives in preparation for the mid-2026 NDA submission for ALXN1840.